Literature DB >> 8325320

New simplified molecular design for functional T cell receptor.

T Brocker1, A Peter, A Traunecker, K Karjalainen.   

Abstract

We have produced a chimeric single-chain T cell receptor (TcR) that combines the specific antibody recognition function and TcR/CD3 signaling properties within the same polypeptide chain. This hybrid molecule consisted of a single-chain antibody combining site that was connected over a short spacer to the transmembrane and cytoplasmic region of CD3 zeta. When expressed on TcR- or TcR+ T cell hybridomas it could mediate recognition of relevant target cells and subsequent production of lymphokines; i.e. it could functionally replace the TcR/CD3 complex. Therefore, the single-chain TcR model presented here represents an interesting and useful means for the creation of T cells with new specificities.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8325320     DOI: 10.1002/eji.1830230705

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  21 in total

1.  The serine and threonine residues in the Ig-alpha cytoplasmic tail negatively regulate immunoreceptor tyrosine-based activation motif-mediated signal transduction.

Authors:  R Müller; J Wienands; M Reth
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-18       Impact factor: 11.205

Review 2.  Versatile CAR T-cells for cancer immunotherapy.

Authors:  Fuliang Chu; Jingjing Cao; Sattva S Neelalpu
Journal:  Contemp Oncol (Pozn)       Date:  2018-03-05

Review 3.  The T-body approach: potential for cancer immunotherapy.

Authors:  Z Eshhar; N Bach; C J Fitzer-Attas; G Gross; J Lustgarten; T Waks; D G Schindler
Journal:  Springer Semin Immunopathol       Date:  1996

Review 4.  Targeting of peripheral blood T lymphocytes.

Authors:  R L Bolhuis; H R Hoogenboom; J W Gratama
Journal:  Springer Semin Immunopathol       Date:  1996

Review 5.  The pharmacology of second-generation chimeric antigen receptors.

Authors:  Sjoukje J C van der Stegen; Mohamad Hamieh; Michel Sadelain
Journal:  Nat Rev Drug Discov       Date:  2015-07       Impact factor: 84.694

Review 6.  Therapeutic T cell engineering.

Authors:  Michel Sadelain; Isabelle Rivière; Stanley Riddell
Journal:  Nature       Date:  2017-05-24       Impact factor: 49.962

Review 7.  CAR therapy: the CD19 paradigm.

Authors:  Michel Sadelain
Journal:  J Clin Invest       Date:  2015-09-01       Impact factor: 14.808

Review 8.  Biology and clinical application of CAR T cells for B cell malignancies.

Authors:  Marco L Davila; Michel Sadelain
Journal:  Int J Hematol       Date:  2016-06-04       Impact factor: 2.490

9.  T cell receptor zeta reconstitution fails to restore responses of T cells rendered hyporesponsive by tumor necrosis factor alpha.

Authors:  Joanna M Clark; Alexander E Annenkov; Manvinder Panesar; Pia Isomäki; Yuti Chernajovsky; Andrew P Cope
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-26       Impact factor: 11.205

Review 10.  Chimeric antigen receptors: driving immunology towards synthetic biology.

Authors:  Michel Sadelain
Journal:  Curr Opin Immunol       Date:  2016-06-30       Impact factor: 7.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.